European Companies Search Engine
UK funding (£656,603): Accelerating paediatric formulation development through smart design and predictive science Ukri 1 Jul 2014 UK Research and Innovation, United Kingdom
Overview
Text
Accelerating paediatric formulation development through smart design and predictive science
| Abstract | This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance. Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design. |
| Category | Collaborative R&D |
| Reference | 101709 |
| Status | Closed |
| Funded period start | 01/07/2014 |
| Funded period end | 31/03/2018 |
| Funded value | £656,603.00 |
| Source | https://gtr.ukri.org/projects?ref=101709 |
Participating Organisations
| ASTRAZENECA UK LIMITED |
£73,889.00 |
| GLAXOSMITHKLINE SERVICES UNLIMITED |
£70,959.00 |
| UNIVERSITY OF BATH |
£92,000.00 |
| JUNIPER PHARMA SERVICES LIMITED |
£60,176.00 |
| ASTON UNIVERSITY |
£14,520.00 |
| UNIVERSITY OF BIRMINGHAM |
£90,704.00 |
| PFIZER LIMITED |
£75,235.00 |
| UNIVERSITY COLLEGE LONDON |
£102,018.00 |
| ACADEMY OF PHARMACEUTICAL SCIENCES |
£3,731.00 |
| BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED |
£73,371.00 |
The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Astrazeneca UK Ltd., Cambridge.